Abstract:Importance: Heart failure with preserved ejection fraction (HFpEF), defined as HF with an EF of 50% or higher at diagnosis, affects approximately 3 million people in the US and up to 32 million people worldwide. Patients with HFpEF are hospitalized approximately 1.4 times per year and have an annual mortality rate of approximately 15%. Observations: Risk factors for HFpEF include older age, hypertension, diabetes, dyslipidemia, and obesity. Approximately 65% of patients with HFpEF present with dyspnea and physical examination, chest radiographic, echocardiographic, or invasive hemodynamic evidence of HF with overt congestion (volume overload) at rest. Approximately 35% of patients with HFpEF present with "unexplained" dyspnea on exertion, meaning they do not have clear physical, radiographic, or echocardiographic signs of HF. These patients have elevated atrial pressures with exercise as measured with invasive hemodynamic stress testing or estimated with Doppler echocardiography stress testing. In unselected patients presenting with unexplained dyspnea, the H2FPEF score incorporating clinical (age, hypertension, obesity, atrial fibrillation status) and resting Doppler echocardiographic (estimated pulmonary artery systolic pressure or left atrial pressure) variables can assist with diagnosis (H2FPEF score range, 0-9; score >5 indicates more than 95% probability of HFpEF). Specific causes of the clinical syndrome of HF with normal EF other than HFpEF should be identified and treated, such as valvular, infiltrative, or pericardial disease. First-line pharmacologic therapy consists of sodium-glucose cotransporter type 2 inhibitors, such as dapagliflozin or empagliflozin, which reduced HF hospitalization or cardiovascular death by approximately 20% compared with placebo in randomized clinical trials. Compared with usual care, exercise training and diet-induced weight loss produced clinically meaningful increases in functional capacity and quality of life in randomized clinical trials. Diuretics (typically loop diuretics, such as furosemide or torsemide) should be prescribed to patients with overt congestion to improve symptoms. Education in HF self-care (eg, adherence to medications and dietary restrictions, monitoring of symptoms and vital signs) can help avoid HF decompensation. Conclusions and relevance: Approximately 3 million people in the US have HFpEF. First-line therapy consists of sodium-glucose cotransporter type 2 inhibitors, exercise, HF self-care, loop diuretics as needed to maintain euvolemia, and weight loss for patients with obesity and HFpEF.

Diagnostic and therapeutic practice for HFpEF across continents and regions: An international survey

Diagnostic and therapeutic practice for Heart Failure with preserved ejection fraction around the world: an international survey

Differences in heart failure with preserved ejection fraction management between care providers: an international survey

Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction

Translating the 2021 ESC heart failure guideline recommendations in daily practice: Results from a heart failure survey. A scientific statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC

Global Differences in Heart Failure with Preserved Ejection Fraction: the Paragon-Hf Trial

Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies

Global differences in acute heart failure treatment: analysis of the STRONG-HF site feasibility questionnaire

[Focus on heart failure with preserved ejection fraction: from trials to the real world of the Friuli-Venezia Giulia Cardiovascular Observatory]

Variability in approach to exercise stress echocardiography for diagnosis of heart failure with preserved ejection fraction: an international survey on real-world practice

Diagnosis of heart failure with preserved ejection fraction based on exercise stress echocardiography in real-world practice

Heart Failure With Preserved Ejection Fraction: Current Status of Daily Clinical Practice in Indonesia

Regional Differences in the Epidemiology of Heart Failure

Understanding the Epidemiology of Heart Failure to Improve Management Practices: an Asia-Pacific Perspective.

The management of heart failure in Sweden—the physician's perspective: a survey

Heart failure with preserved ejection fraction: A growing global epidemic

Heart Failure With Preserved Ejection Fraction: A Review

Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey

Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape

Heart failure outcomes by left ventricular ejection fraction in a contemporary region‐wide patient cohort

Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement